Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2025-01-01

Summary

Breast cancer is rarely curable after metastasis, and the therapeutic options are limited. Interestingly, the host immune response is strongly predictive for the effect of chemotherapy in subgroups of patients with breast cancer. The aim is to release the brake on the immune response by use of ipilimumab, which blocks CTLA-4 and may deplete regulatory T cells, combined with nivolumab (anti PD1). Importantly, it is possible that non-responders to nivolumab/ipilimumab (nivo/ipi) can be turned responders by use of immunogenic chemotherapy.

• Phase: Phase 2

Details

• Lead Sponsor: Oslo University Hospital
• Collaborators: Bristol-Myers Squibb; Centre Hospitalier Universitaire Dinant Godinne - UCL Namur; Cliniques universitaires Saint-Luc- Université Catholique de Louvain; Helse Sor-Ost; Helse Stavanger HF; Jules Bordet Institute; Sorlandet Hospital HF
• Treatments: Antibodies, Monoclonal; Cyclophosphamide; Doxorubicin; Ipilimumab; Liposomal doxorubicin; Nivolumab